Salix Receives Purported Notice of Paragraph IV Certification Against Patent for MOVIPREP(R)

redorbit.com     Apr 9, 2008            

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Company and its licensor, Norgine B.V., have received a purported notice of Paragraph IV Certification on behalf of Novel Laboratories, Inc. ... advising of the submission of an Abbreviated New Drug... [read full story]                    

FULL COVERAGE

Salix Receives Purported Notice of Paragraph IV Certification Against Patent for MOVIPREP(R)...

yahoo.com     Apr 9, 2008          

RALEIGH, N.C.----Salix Pharmaceuticals, Ltd. today announced that the Company and its licensor, Norgine B.V., have received a purported notice of Paragraph IV Certification on behalf of Novel Laboratories, Inc. advising of the submission of an Abbreviated New Drug Application for MOVIPREP® .                    

comments

Salix Bowel Drug Patent Challenged (AP)

yahoo.com     Apr 9, 2008          

Drug developer Salix Pharmaceuticals Ltd. said Wednesday Novel Laboratories is challenging the patent on the company's bowel cleansing drug Moviprep. ... The drug is licensed to Salix by Netherlands-based Norgine B.V., which is privately held. The company said privately...                    

comments

Salix Bowel Drug Patent Challenged

ibtimes.com     Apr 9, 2008          

Drug developer Salix Pharmaceuticals Ltd. said Wednesday Novel Laboratories is challenging the patent on the company's bowel cleansing drug Moviprep. The drug is licensed to Salix by Netherlands-based Norgine B.V., which is privately held. ... The company said privately...                    

comments

Salix Bowel Drug Patent Challenged

chron.com     Apr 9, 2008          

RALEIGH, N.C. — Drug developer Salix Pharmaceuticals Ltd. said Wednesday Novel Laboratories is challenging the patent on the company's bowel cleansing drug Moviprep. The drug is licensed to Salix by Netherlands-based Norgine B.V., which is privately held.                    

comments